This summary of the 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

# Submitter:

INOVA Diagnostics, Inc 9900 Old Grove Road, San Diego, CA, 92131

# Purpose of submission:

New device

Scientific contact:

Gabriella Lakos, Director of Research, Rheumatology   
INOVA Diagnostics, Inc   
9900 Old Grove Road, San Diego, CA, 92131   
Phone: 858-586-9900/393   
Fax: 858-863-0025   
email: glakos@sd.inovadx.com

Quality Systems contact:

Tana Keivens, Director, Quality Systems   
INOVA Diagnostics, Inc   
9900 Old Grove Road, San Diego, CA, 92131   
Phone: 858-586-9900   
Fax: 858-863-0025/351   
email: tkeivens@sd.inovadx.com

# Preparation date:

09/10/2012 (amended on 09/28/2012)

Device name (assay kits):

Proprietary name: Common name: Classification name:

QUANTA Flash™ DGP IgA   
QUANTA Flash™ DGP IgG   
DGP IgA Chemiluminescent Immunoassay DGP IgG Chemiluminescent Immunoassay Antibodies, Gliadin (21 CCFR 862.1690)

# Regulation Description

Radioallergosorbent (RAST) immunological test system

Regulation Medical Specialty   
Review Panel   
Product Code   
Regulation Number   
Device Class Immunology Immunology MST   
866.5750   
2

Device name (Calibrators):

Proprietary name: QUANTA Flash™ DGP IgA Calibrators QUANTA Flash™ DGP IgG Calibrators   
Common name: DGP IgA Calibrators DGP IgG Calibrators   
Classification name: Calibrator, secondary   
Regulation Description   
Regulation Medical Specialty   
Product Code   
Regulation Number   
Device Class   
Calibrator   
Clinical Chemistry   
JIT   
862.1150   
2

Device name (Controls):

Proprietary name: Common name: Classification name:

# Regulation Description

Quality control material (assayed and unassayed)

Regulation Medical Specialty   
Product Code   
Regulation Number   
Device Class

Predicate device(s): QUANTA Lite™ Gliadin IgA II, 510(k) number: K052143   
QUANTA Lite™ Gliadin IgG II, 510(k) number: K052142

# Device description:

Synthetic deamidated gliadin peptide is coated onto the surface of paramagnetic beads (microparticles), which are stored nthereagentcartriender conditions that preservetheantigen nt reactiv ate. The reagent cartridge is then loaded onto and used by the BIO-FLASH instrument.

Serum samples are prediluted by the instrument with system rinse buffer, and added to disposable plastic cuvettes. Small amounts of the diluted patient serum, the DGP beads, and assay buffer are all combined into a second cuvette, and mixed. This cuvette is incubated at $\Im 7 ^ { \circ } C$ , The beads are then magnetized and washed several times. Isoluminol conjugated anti-human IgA (or IgG) antibody is then added to the cuvette, and incubated at $\mathsf { \mathsf { 3 7 ^ { \circ } C } }$ Again, the beads are magnetized and washed repeatedly. The isoluminol conjugate produces a luminescent reaction when reagents ("Triggers") are added to the cuvette. The light produced from this reaction is measured as Relative Light Units (RLU) by the BIOFLASH optical system. The RLU are proportional to the amount of bound isoluminol conjugate, which in turn is proportional to the amount of anti-DGP antibodies bound to the DGP on the beads.

For quantitation, the QUANTA Flash DGP IgA and IgG assays utilize a predefined lot specific Master Curve that is uploaded onto the instrument through the reagent cartridge barcode. Every new lot number of reagent cartrige must be calibrated before first use with the QuANTA Flash DGP IgA and IgG Calibrators. Based on the results obtained with the two Calibrators included in the Calibrator et, an instrument specific Working Curve is created, which is used to calculate chemiluminescent units (CU)

from the RLU obtained for each patient.

The QUANTA Flash DGP IgA reagent cartridge contains the following reagents:

a. DGP coated paramagnetic beads in buffer, containing protein stabilizers and preservative.   
b. Assay buffer - colored pink, containing Tris-buffered saline, Tween 20, protein stabilizers and preservatives.   
C. Tracer IgA - Isoluminol labeled anti-human IgA antibodies in buffer, containing protein stabilizers and preservative.

The QUANTA Flash DGP IgG reagent cartridge contains the following reagents:

a. DGP coated paramagnetic beads in buffer, containing protein stabilizers and preservative.   
b. Assay buffer - colored pink, containing Tris-buffered saline, Tween 20, protein stabilizers and preservatives.   
C. Tracer IgG - Isoluminol labeled anti-human IgA antibodies in buffer, containing protein stabilizers and preservative.

The QUANTA Flash™ DGP IgA Calibrators and the QUANTA Flash™ DGP IgG Calibrators kits each contain 2 vials of Calibrators:

QUANTA Flash™ DGP IgA Calibrators:

QUANTA Flash DGP IgA Calibrator 1: Two (2) barcode labeled tubes containing $0 . 3 \ \mathsf { m L }$ prediluted, ready to use reagent. Calibrators contain human IgA antibodies to DGP in buffer, protein stabilizers, and preservatives.   
QUANTA Flash DGP IgA Calibrator 2: Two (2) barcode labeled tubes containing $0 . 3 \ m L$ prediluted, ready to use reagent. Calibrators contain human IgA antibodies to DGP in buffer, protein stabilizers, and preservatives.

QUANTA Flash™ DGP IgG Calibrators:

QUANTA Flash DGP IgG Calibrator 1: Two (2) barcode labeled tubes containing $0 . 3 \ m L$ prediluted, ready to use reagent. Calibrators contain human IgG antibodies to DGP in buffer, protein stabilizers, and preservatives.   
QUANTA Flash DGP IgG Calibrator 2: Two (2) barcode labeled tubes containing $\mathbf { 0 . 3 \ m L }$ prediluted, ready to use reagent. Calibrators contain human IgG antibodies to DGP in buffer, protein stabilizers, and preservatives.

The QUANTA Flash™ DGP IgA Controls kit and the QUANTA Flash™ DGP IgG Controls kits each contain 2 vials of Negative Control and two vials of Positive Control:

QUANTA Flash™ DGP IgA Controls:

QUANTA Flash™ DGP IgA Negative Control: Two (2) barcode labeled tubes containing 0.5 mL, ready to use reagent. Controls contain human IgA antibodies to DGP in buffer, protein stabilizers, and preservatives. QUANTA Flash™ DGP IgA Positive Control: Two (2) barcode labeled tubes containing $0 . 5 m l ,$ ready to use reagent. Controls contain human IgA antibodies to DGP in buffer, protein

stabilizers, and preservatives.

QUANTA Flash™ DGP IgG Controls: QUANTA Flash™ DGP IgG Negative Control: Two (2) barcode labeled tubes containing 0.5 mL, ready to use reagent. Controls contain human IgG antibodies to DGP in buffer, protein stabilizers, and preservatives. QUANTA Flash™ DGP IgG Positive Control: Two (2) barcode labeled tubes containing $0 . 5 m 1$ . ready to use reagent. Controls contain human IgG antibodies to DGP in buffer, protein stabilizers, and preservatives.

# Intended use:

The QUANTA Flash™ DGP IgA is a chemiluminescent immunoassay for the semi-quantitative determination of of IgA antibodies to synthetic, deamidated gliadin peptides in human serum. The measurement of IgA deamidated gliadin peptide antibodies can be used in conjunction with clinical findings andother laboratory tests to aid in the diagnosi  celia disease and dermatitis herpetiformis.

The QUANTA Flash™ DGP IgG is a chemiluminescent immunoassay for the semi-quantitative detection of IgG antibodies to synthetic, deamidated gliadin peptides in human serum. The measurement of IgG deamidated gliadin peptide antibodies can be used in conjunction with clinical findings and other laboratory tests to aidinthe diagnosisof celiac disease in gA sufficient and IgA deficient patients, as well as dermatitis herpetiformis.

The QUANTA Flash DGP IgA Calibrators are intended for use with the QUANTA Flash DGP IgA chemiluminescentmmunoassay (CIA). Each calibrator establishes a point f reference or the workingcrve tha is used o determine Chemiluminecent Unit (U) values n the measurement  gA antiG antibodis in serum.

The QUANTA Flash DGP IgA Calibrators are intended for use with the QUANTA Flash DGP IgA chemiluminescent mmunoassay (CIA). Each calibrator establishes a point  reference or the working crve tha is used o determie hemilumiecent Unit U) values  hemeasurement  AantG antibi in serum.

The QUANTA Flash DGP IgA Controls are intended for quality control purposes of the QUANTA Flash DGP IgA chemiluminescent immunoassay (CIA) kit run on the BIO FLASH® instrument that is used for the measurement of IgA anti-deamidated gliadin peptide (DGP) antibodies in human serum.

The QUANTA Flash DGP IgG Controls are intended for quality control purposes of the QUANTA Flash DGP IgG chemiluminescent immunoassay (CIA) kit run on the BIO FLASH® instrument that is used for the measurement of IgG anti-deamidated gliadin peptide (DGP) antibodies in human serum.

# Substantial equivalence:

The QUANTA Flash™ DGP IgA assay, the QUANTA Flash DGP IgA Calibrators and the QUANTA Flash DGP IgA Controls have the same intended use and assay principle as the predicate device. The QUANTA Flash™ DGP IgG assay, the QUANTA Flash DGP IgAG Calibrators and the QUANTA Flash DGP IgG Controls have the same intended use and assay principle as the predicate device.

# Comparison to predicate device:

QUANTA Flash DGP IgA reagent kit   

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>QUANTA Flash DGP IgA</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Semi-quantitative determination ofIgA antibodies to synthetic,deamidated gliadin peptides in humanserum.</td><td rowspan=1 colspan=1>Semi-quantitative detection of IgAantibodies to gliadin in human serum</td></tr><tr><td rowspan=1 colspan=1>Assay methodology</td><td rowspan=1 colspan=1>Solid phase (heterogenous)immunoassay</td><td rowspan=1 colspan=1>Solid phase (heterogeneous)immunoassay</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>International Reference Preparation isnot available</td><td rowspan=1 colspan=1>International Reference Preparation isnot available</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>Synthetic, deamidated gliadinpeptides</td><td rowspan=1 colspan=1>Synthetic, deamidated gliadin peptides</td></tr><tr><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Shelf life</td><td rowspan=1 colspan=1>One year</td><td rowspan=1 colspan=1>One year</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>QUANTA Flash DGP IgA</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Detection/Operating principle</td><td rowspan=1 colspan=1>Chemiluminescent immunoassay</td><td rowspan=1 colspan=1>Enzyme-linked immunosorbent assay</td></tr><tr><td rowspan=1 colspan=1>Solid phase</td><td rowspan=1 colspan=1>Paramagnetic microparticles (beads)</td><td rowspan=1 colspan=1>96-well plate</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Isoluminol conjugated anti-human IgA</td><td rowspan=1 colspan=1>HRP conjugated anti-human IgA</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>Lot specific Master Curve + twoCalibrators (Sold separately)</td><td rowspan=1 colspan=1>Gliadin IgA II ELISA Low PositiveGliadin IgA II ELISA High Positive(Included in the kit)</td></tr></table>

# QUANTA Flash DGP IgG reagent kit

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">QUANTA Flash DGP IgG</td><td colspan="1" rowspan="1">Predicate Device</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">Semi-quantitative determination ofIgG antibodies to synthetic,deamidated gliadin peptides inhuman serum.</td><td colspan="1" rowspan="1">Semi-quantitative detection of IgGantibodies to gliadin in human serum</td></tr><tr><td colspan="1" rowspan="1">Assay methodology</td><td colspan="1" rowspan="1">Solid phase (heterogenous)immunoassay</td><td colspan="1" rowspan="1">Solid phase (heterogenous)immunoassay</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">International Reference Preparationis not available</td><td colspan="1" rowspan="1">International Reference Preparation isnot available</td></tr><tr><td colspan="1" rowspan="1">Antigen</td><td colspan="1" rowspan="1">Synthetic, deamidated gliadinpeptides</td><td colspan="1" rowspan="1">Synthetic, deamidated gliadin peptides</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Serum</td></tr><tr><td colspan="1" rowspan="1">Shelf life</td><td colspan="1" rowspan="1">One year</td><td colspan="1" rowspan="1">One year</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">QUANTA Flash DGP IgG</td><td colspan="1" rowspan="1">Predicate Device</td></tr><tr><td colspan="1" rowspan="1">Detection/Operating principle</td><td colspan="1" rowspan="1">Chemiluminescent immunoassay</td><td colspan="1" rowspan="1">Enzyme-linked immunosorbent assay</td></tr><tr><td colspan="1" rowspan="1">Solid phase</td><td colspan="1" rowspan="1">Paramagnetic microparticles (beads)</td><td colspan="1" rowspan="1">96-well plate</td></tr><tr><td colspan="1" rowspan="1">Conjugate</td><td colspan="1" rowspan="1">Isoluminol conjugated anti-humanIgG</td><td colspan="1" rowspan="1">HRP conjugated anti-human IgG</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Lot specific Master Curve + twocalibrators (Sold separately)</td><td colspan="1" rowspan="1">Gliadin IgG II ELISA Low PositiveGliadin IgG II ELISA High Positive(Included in the kit)</td></tr></table>

# QUANTA Flash DGP IgA Calibrators

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>QUANTA Flash DGP IgA Calibrators</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>For use with the QUANTA Flash DGPIgA chemiluminescent immunoassay(CIA). Each calibrator establishes apoint of reference for the workingcurve that is used to determineChemiluminescent Unit (CU) valuesin the measurement of IgA anti-DGPantibodies in serum.</td><td rowspan=1 colspan=1>No separate intended use;calibrators are part of the kit.</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>DGP IgA antibodies</td><td rowspan=1 colspan=1>DGP IgA antibodies</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>QUANTA Flash™ DGP IgA,chemiluminescent immunoassay</td><td rowspan=1 colspan=1>QUANTA Lite™ Gliadin IgA II, ELISA</td></tr><tr><td rowspan=1 colspan=1>Unit</td><td rowspan=1 colspan=1>CU (Chemiluminescent units)(arbitrary)</td><td rowspan=1 colspan=1>Units (arbitray)</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human serum, buffer, stabilizers,preservative</td><td rowspan=1 colspan=1>Human serum, buffer, stabilizers,preservative</td></tr><tr><td rowspan=1 colspan=1>Physico-chemicalcharacteristics</td><td rowspan=1 colspan=1>Liquid, ready to use</td><td rowspan=1 colspan=1>Liquid, ready to use</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>2-8°</td><td rowspan=1 colspan=1>2-8°</td></tr><tr><td rowspan=1 colspan=1>Shelf life</td><td rowspan=1 colspan=1>One year</td><td rowspan=1 colspan=1>One year</td></tr><tr><td rowspan=1 colspan=1>In-use stability</td><td rowspan=1 colspan=1>Four calibrations, maximum total 8hours uncapped onboard theinstrument.</td><td rowspan=1 colspan=1>Calibrators can be used until the endof the shelf life when storedproperly</td></tr></table>

QUANTA Flash DGP IgG Calibrators   

<table><tr><td>Item</td><td>QUANTA Flash DGP IgG Calibrators</td><td>Predicate Device</td></tr><tr><td>Intended use</td><td>For use with the QUANTA Flash DGP IgG chemiluminescent immunoassay (CIA). Each calibrator establishes a point of reference for the working curve that is used to determine Chemiluminescent Unit (CU) values</td><td>No separate intended use; calibrators are part of the kit.</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">in the measurement of IgG anti-DGPantibodies in serum.</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">DGP IgG antibodies</td><td colspan="1" rowspan="1">DGP IgG antibodies</td></tr><tr><td colspan="1" rowspan="1">Method</td><td colspan="1" rowspan="1">QUANTA Flash™ DGP IgG,chemiluminescent immunoassay</td><td colspan="1" rowspan="1">QUANTA Lite™ Gliadin IgG II, ELISA</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Human serum, buffer, stabilizers,preservative</td><td colspan="1" rowspan="1">Human serum, buffer, stabilizers,preservative</td></tr><tr><td colspan="1" rowspan="1">Unit</td><td colspan="1" rowspan="1">CU (Chemiluminescent units)(arbitrary)</td><td colspan="1" rowspan="1">Units (arbitray)</td></tr><tr><td colspan="1" rowspan="1">Physico-chemicalcharacteristics</td><td colspan="1" rowspan="1">Liquid, ready to use</td><td colspan="1" rowspan="1">Liquid, ready to use</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">2-8°</td><td colspan="1" rowspan="1">2-8°</td></tr><tr><td colspan="1" rowspan="1">Shelf life</td><td colspan="1" rowspan="1">One year</td><td colspan="1" rowspan="1">One year</td></tr><tr><td colspan="1" rowspan="1">In-use stability</td><td colspan="1" rowspan="1">Four calibrations, maximum total 8hours uncapped onboard theinstrument.</td><td colspan="1" rowspan="1">Calibrators can be used until the endof the shelf life when storedproperly</td></tr></table>

# QUANTA Flash DGP IgA Controls

<table><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">QUANTA Flash DGP IgA Controls</td><td colspan="1" rowspan="1">Predicate Device</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">Quality control purposes of theQUANTA    Flash    DGP    IgAchemiluminescent    immunoassay(CIA) kit.</td><td colspan="1" rowspan="1">No separate intended use; controlsare part of the kit.</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">DGP IgA antibodies</td><td colspan="1" rowspan="1">DGP IgA antibodies</td></tr><tr><td colspan="1" rowspan="1">Method</td><td colspan="1" rowspan="1">QUANTA Flash™ DGP IgA,chemiluminescent immunoassay</td><td colspan="1" rowspan="1">QUANTA Lite™ Gliadin IgA II, ELISA</td></tr><tr><td colspan="1" rowspan="1">Unit</td><td colspan="1" rowspan="1">CU (Chemiluminescent units)(arbitrary)</td><td colspan="1" rowspan="1">Units (arbitray)</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Human serum, buffer, stabilizers,preservative</td><td colspan="1" rowspan="1">Human serum, buffer, stabilizers,preservative</td></tr><tr><td colspan="1" rowspan="1">Physico-chemicalcharacteristics</td><td colspan="1" rowspan="1">Liquid, ready to use</td><td colspan="1" rowspan="1">Liquid, ready to use</td></tr><tr><td colspan="1" rowspan="1">Levels</td><td colspan="1" rowspan="1">2 (negative and positive)</td><td colspan="1" rowspan="1">3: (ELISA negative, low positive, highpositive</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">2-8 </td><td colspan="1" rowspan="1">2-8°</td></tr><tr><td colspan="1" rowspan="1">Shelf life</td><td colspan="1" rowspan="1">One year</td><td colspan="1" rowspan="1">One year</td></tr><tr><td colspan="1" rowspan="1">In-use stability</td><td colspan="1" rowspan="1">15 uses, with a maximum time of 10minutes onboard the instrument peruse, or 2 ½ hours, total.</td><td colspan="1" rowspan="1">Controls can be used until the endof the shelf life when storedproperly</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">QUANTA Flash DGP IgG Controls</td><td colspan="1" rowspan="1">Predicate Device</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">Quality control purposes of theQUANTA    Flash    DGP    IgGchemiluminescent    immunoassay(CIA) kit.</td><td colspan="1" rowspan="1">No separate intended use; controlsare part of the kit.</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">DGP IgG antibodies</td><td colspan="1" rowspan="1">DGP IgG antibodies</td></tr><tr><td colspan="1" rowspan="1">Method</td><td colspan="1" rowspan="1">QUANTA Flash™ DGP IgG,chemiluminescent immunoassay</td><td colspan="1" rowspan="1">QUANTA Lite™ Gliadin IgG II, ELISA</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Human serum, buffer, stabilizers,preservative</td><td colspan="1" rowspan="1">Human serum, buffer, stabilizers,preservative</td></tr><tr><td colspan="1" rowspan="1">Unit</td><td colspan="1" rowspan="1">CU (Chemiluminescent units)(arbitrary)</td><td colspan="1" rowspan="1">Units (arbitray)</td></tr><tr><td colspan="1" rowspan="1">Physico-chemicalcharacteristics</td><td colspan="1" rowspan="1">Liquid, ready to use</td><td colspan="1" rowspan="1">Liquid, ready to use</td></tr><tr><td colspan="1" rowspan="1">Levels</td><td colspan="1" rowspan="1">2 (negative and positive)</td><td colspan="1" rowspan="1">3: (ELISA negative, low positive, highpositive)</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">2-8°</td><td colspan="1" rowspan="1">2-8 </td></tr><tr><td colspan="1" rowspan="1">Shelf life</td><td colspan="1" rowspan="1">One year</td><td colspan="1" rowspan="1">One year</td></tr><tr><td colspan="1" rowspan="1">In-use stability</td><td colspan="1" rowspan="1">15 uses, with a maximum time of 10minutes onboard the instrument peruse, or 2 % hours, total.</td><td colspan="1" rowspan="1">Controls can be used until the endof the shelf life when storedproperly</td></tr></table>

# Value assignment and traceability of Calibrators and Controls

The QUANTA Flash DGP IgA and IgG Calibrators and Controls are manufactured by diluting human serum that contains high titer of IgA or IgG anti-DGP antibodies into a buffer containing stabilizers and preservative. The human serum is obtained from commercial sources and it is tested for markers of infectious substances.

The target CU is achieved through trial dilutions on smallscale. Once a dilution is selected, the Calibrators and Control are bulked, tested, and adjusted. Upon completion of the manufacturing process, the Calibrators and Controls are tested on at least two instruments, on at least two lots of reagent cartridge, in replicates of 10 to determine final value assignment.

There are currently no recognized international standards for the measurement of IgA and IgG anti deamidated gliadin peptide antibodies.

Calibrator and Control values are directly traceable to in-house Standards that are used to create the Master Curve for the QUANTA Flash™ DGP IgA and QUANTA Flash™ DGP IgG assay.

# Performance characteristics

# Precision

The precision of the QUANTA Flash DGP IgA assay was evaluated on 8 samples containing various concentrations of DGP IgA antibodies in accordance with CLSI EP5-A2, Evaluation of Precision Performance of Quantitative Measurement Procedures - Approved Guideline: samples were run in duplicates, twice a day, for at least 20 days. Data were analyzed with the Analyse-it for Excel method evaluation software, and within run, between run, between day and total precisions are summarized in the Table below. All %CV values were within the acceptance limit, $1 5 \%$ .

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>Within-RunPrecision(repeatability)</td><td rowspan=1 colspan=2>Between-RunPrecision</td><td rowspan=1 colspan=2>Between-DayPrecision</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1>Sample ID</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Mean(CU))</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>105.6</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>6.4%</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>8.2%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>35.1</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>5.9%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>10.7%</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>12.2%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>15.4</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>5.8%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>6.2%</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>8.5%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>32.4</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>6.8%</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>7.5%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>128.8</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>4.6%</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>6.7%</td><td rowspan=1 colspan=1>11.2</td><td rowspan=1 colspan=1>8.7%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>10.5</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>4.0%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>5.8%</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>7.3%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>33.0</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>8.8%</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>9.7%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>76</td><td rowspan=1 colspan=1>1930.8</td><td rowspan=1 colspan=1>94.9</td><td rowspan=1 colspan=1>4.9%</td><td rowspan=1 colspan=1>63.8</td><td rowspan=1 colspan=1>3.3%</td><td rowspan=1 colspan=1>149.7</td><td rowspan=1 colspan=1>7.8%</td><td rowspan=1 colspan=1>188.4</td><td rowspan=1 colspan=1>9.8%</td></tr></table>

The precision of the QUANTA Flash DGP IgG assay was evaluated on 8 samples containing various concentrations of DGP IgG antibodies in accordance with CLSI EP5-A2, Evaluation of Precision Performance of Quantitative Measurement Procedures - Approved Guideline: samples were run in duplicates, twice a day, for at least 20 days. Data were analyzed with the Analyse-it for Excel method evaluation software, and within run, between run, between day and total precision are summarized in the Table below. All %CV values were within the acceptance limit, $1 5 \%$ .

<table><tr><td rowspan=1 colspan=3></td><td rowspan=1 colspan=2>Within-RunPrecision(repeatability)</td><td rowspan=1 colspan=2>Between-RunPrecision</td><td rowspan=1 colspan=2>Between-DayPrecision</td><td rowspan=1 colspan=2>Total Precision</td></tr><tr><td rowspan=1 colspan=1>Sample ID</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Mean (CU)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>4.5%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>16.8</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>3.3%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>20.7</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.6%</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>24.6</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.0%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>85.1</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>3.8%</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>411.6</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>13.9</td><td rowspan=1 colspan=1>3.4%</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>791.0</td><td rowspan=1 colspan=1>24.3</td><td rowspan=1 colspan=1>3.1%</td><td rowspan=1 colspan=1>16.2</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>29.8</td><td rowspan=1 colspan=1>3.8%</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1781.4</td><td rowspan=1 colspan=1>52.1</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>27.9</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>48.3</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>76.3</td><td rowspan=1 colspan=1>4.3%</td></tr></table>

Additinally, precisin studies were also performed at three different testing ites tobe able tocalculate between-sites (between-nstruments) precision.Results that were obtained in the research laboratory of INOvA were compared to those obtained on the same specimens in a hospital (Akron City Hospital, Summa Health System, 525 East Market Street, Akron, Ohio 44304) and in an academic laboratory (Mitogen Advanced Diagnostics Laboratory, The University of Calgary, Faculty of Medicine, #431,3330 Hospital Dr NW, Calgary, AB T2N 4N1, CANADA).

T   a  ne-  n e oi tested at each site. Samples were run in duplicates four times a day, for 10 days, resulting in 80 individual data points. Two reagent lots, two calibrator lots and two operators were included as variables at the INOVA site.

Between sites/instruments SD and $\% C V$ valu we calculated with the Analys r xce sotware, and the results are presented below as pair-wise comparisons between the sites.

Moreover, total between-sites reproducibility was calculated based on the pair-wise comparisons, and it was used to calculate Total Reproducibility, taking into account within run, between run, between lots, between calibrator lots, between operators and between sites precision.

Acceptance criterion was $\leq 1 5 \%$ for all reproducibility studies.

DGP IgA, Sample 1   
Blue: %CV Red: average (CU)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>INOVA</td><td rowspan=1 colspan=1>Mitogen AdvancedDiagnostics</td><td rowspan=1 colspan=1>ed</td><td rowspan=1 colspan=1>Summa HealthSystem</td></tr><tr><td rowspan=1 colspan=1>INOVA</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>12.6</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>12.6</td></tr><tr><td rowspan=1 colspan=1>Mitogen AdvancedDiagnostics</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>12.3</td></tr><tr><td rowspan=1 colspan=1>Summa HealthSystem</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1></td></tr></table>

# DGP IgA, Sample 2

Blue: %CV Red: average (CU)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>INOVA</td><td rowspan=1 colspan=2>Mitogen AdvancedDiagnostics</td><td rowspan=1 colspan=1>Summa HealthSystem</td></tr><tr><td rowspan=1 colspan=1>INOVA</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>25.4</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>25.1</td></tr><tr><td rowspan=1 colspan=1>Mitogen AdvancedDiagnostics</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>25.0</td></tr><tr><td rowspan=1 colspan=1>Summa HealthSystem</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

DGP IgA, Sample 3   
Blue: %CV Red: average (CU)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>INOVA</td><td rowspan=1 colspan=2>Mitogen AdvancedDiagnostics</td><td rowspan=1 colspan=1>Summa HealthSystem</td></tr><tr><td rowspan=1 colspan=1>INOVA</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>137.1</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>132.8</td></tr><tr><td rowspan=1 colspan=1>Mitogen AdvancedDiagnostics</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>132.9</td></tr><tr><td rowspan=1 colspan=1>Summa HealthSystem</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

DGP IgG, Sample 1 Blue: %CV Red: average (CU)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>INOVA</td><td rowspan=1 colspan=1>Mitogen AdvancedDiagnostics</td><td rowspan=1 colspan=1>ed</td><td rowspan=1 colspan=1>SummaHealth System</td></tr><tr><td rowspan=1 colspan=1>INOVA</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>13.0</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>12.8</td></tr><tr><td rowspan=1 colspan=1>Mitogen AdvancedDiagnostics</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>12.5</td></tr><tr><td rowspan=1 colspan=1>Summa HealthSystem</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1></td></tr></table>

DGP IgG, Sample 2 Blue: %CV Red: average (CU)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>INOVA</td><td rowspan=1 colspan=1>Mitogen AdvancedDiagnostics</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>SummaHealth Care</td></tr><tr><td rowspan=1 colspan=1>INOVA</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>20.5</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>20.2</td></tr><tr><td rowspan=1 colspan=1>Mitogen AdvancedDiagnostics</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>19.7</td></tr><tr><td rowspan=1 colspan=1>Summa Health Care</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1></td></tr></table>

DGP IgG, Sample 3   
Blue: %CV Red: average (CU)   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>INOVA</td><td rowspan=1 colspan=1>Mitogen AdvancedDiagnostics</td><td rowspan=1 colspan=1>ed</td><td rowspan=1 colspan=1>SummaHealth Care</td></tr><tr><td rowspan=1 colspan=1>INOVA</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>118.4</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1>114.1</td></tr><tr><td rowspan=1 colspan=1>Mitogen AdvancedDiagnostics</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>113.5</td></tr><tr><td rowspan=1 colspan=1>Summa Health Care</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>−</td><td rowspan=1 colspan=1></td></tr></table>

# DGP IgA Total Reproducibility summary table:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>BetweenRun</td><td rowspan=1 colspan=2>BetweenReagentLots</td><td rowspan=1 colspan=2>BetweenCalibratorLots</td><td rowspan=1 colspan=2>BetweenOperators</td><td rowspan=1 colspan=2>BetweenSites</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(CU)</td><td rowspan=1 colspan=1>Number ofreplicates</td><td rowspan=1 colspan=1>SD(CU)</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD(CU)</td><td rowspan=1 colspan=1>Cv(%)</td><td rowspan=1 colspan=1>SD(CU)</td><td rowspan=1 colspan=1>Cv(9%)</td><td rowspan=1 colspan=1>SD(CU)</td><td rowspan=1 colspan=1>CV(9%)</td><td rowspan=1 colspan=1>SD(CU)</td><td rowspan=1 colspan=1>Cv(%)</td><td rowspan=1 colspan=1>SD(CU)</td><td rowspan=1 colspan=1>Cv(%)</td><td rowspan=1 colspan=1>SD(CU)</td><td rowspan=1 colspan=1>cv(%)</td></tr><tr><td rowspan=1 colspan=1>Sample#1</td><td rowspan=1 colspan=1>12.9</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>5.6</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>14.8</td></tr><tr><td rowspan=1 colspan=1>Sample#2</td><td rowspan=1 colspan=1>25.5</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>12.6</td></tr><tr><td rowspan=1 colspan=1>Sample#3</td><td rowspan=1 colspan=1>136.8</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>10.4</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>11.2</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>20.1</td><td rowspan=1 colspan=1>14.7</td></tr></table>

# DGP IgG Total Reproducibility summary table:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>BetweenRun</td><td rowspan=1 colspan=2>BetweenReagentLots</td><td rowspan=1 colspan=2>BetweenCalibratorLots</td><td rowspan=1 colspan=2>BetweenOperators</td><td rowspan=1 colspan=2>BetweenSites</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean(CU)</td><td rowspan=1 colspan=1>Number ofreplicates</td><td rowspan=1 colspan=1>SD(CU)</td><td rowspan=1 colspan=1>Cv(%)</td><td rowspan=1 colspan=1>SD(CU)</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD(CU)</td><td rowspan=1 colspan=1>Cv(%)</td><td rowspan=1 colspan=1>SD(CU)</td><td rowspan=1 colspan=1>Cv(%)</td><td rowspan=1 colspan=1>SD(CU)</td><td rowspan=1 colspan=1>Cv(%)</td><td rowspan=1 colspan=1>SD(CU)</td><td rowspan=1 colspan=1>cv(%)</td><td rowspan=1 colspan=1>SD(CU)</td><td rowspan=1 colspan=1>Cv(%)</td></tr><tr><td rowspan=1 colspan=1>Sample#1</td><td rowspan=1 colspan=1>13.4</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>13.5</td></tr><tr><td rowspan=1 colspan=1>Sample#2</td><td rowspan=1 colspan=1>21.0</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>12.9</td></tr><tr><td rowspan=1 colspan=1>Sample#3</td><td rowspan=1 colspan=1>118.9</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>13.0</td><td rowspan=1 colspan=1>10.9</td></tr></table>

# Limit of Blank, Limit of Detection

QUANTA Flash DGP IgA:

The Limit of Detection (LoD) of the QUANTA Flash™ DGP IgA assay is 730.3 RLU, which is below the analytical measuring range of the assay. It was determined consistent with CLSI EP17-A guideline with proportions of false positives (alpha) less than $5 \%$ and false negatives (beta) less than $5 \%$ ; based on 140 determinations, with 60 blank and 80 low level samples. The LoB is 504.9 RLU.

QUANTA Flash DGP IgG:

The Limit of Detection (LoD) of the QUANTA Flash™ DGP IgG assay is 469.2 RLU, which is below the analytical measuring range of the assay. It was determined consistent with CLSI EP17-A guideline with proportions of false positives (alpha) less than $5 \%$ and false negatives (beta) less than $5 \%$ ; based on 140 de

terminations, with 60 blank and 80 low level samples. The LoB is 257.7 RLU.

# Analytical Measuring Range

QUANTA Flash DGP IgA:

QUANTA Flash DGP IgG:

5.2 CU - 2367.3 CU   
2.8 CU -1936.7 CU

# Cut-off, reference range

QUANTA Flash DGP IgA:

Negative <20 CU Weak Positive 20-30 CU Positive >30 CU

QUANTA Flash DGP IgG :

Negative <20 CU Weak Positive 20-30 CU Positive >30 CU

QUANTA Flash DGP IgA The control population for establishing the reference interval for the DGP IgA assay consisted of 355 subjects:   

<table><tr><td rowspan=1 colspan=1>Apparently healthy blood bank donors</td><td rowspan=1 colspan=1>201</td></tr><tr><td rowspan=1 colspan=1>Inflammatory bowel disease</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>H. pylori infection</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>Autoimmune thyroid disease</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Infectious diseases</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid arthritis</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Patients with antinuclear antibodies</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Controls tTG workshop study from Dr. Liu atChildren&#x27;s Hospital and University of Colorado.</td><td rowspan=1 colspan=1>50</td></tr></table>

All specimens were the same matrix (serum) as specified in the Intended Use. All specimens were unaltered. The cut off was established in accordance to CLSI C28-A3c: Defining, Establishing, and Veriying Reference Intervals inthe Clinical LaboratoryApproved Guideline-ThirdEdition.TheAnalyse it r Excel software was used to make the calculations. The distribution of the results was non-normal (Saphiro-Wilk $\mathsf { p } { \mathsf { < } } 0 . 0 0 0 1 ^ { \prime }$ ), so the non-parametric percentile method was used. The 99th percentile of the RLU values was 677.To ensre high specificity, the 800 RLU value was selected as cut-ofThis value provided the combination of the highest sensitivity and specificity based on the results obtained on 37 CD specimens that were tested together with the control population. The value of 20 chemiluminescent units

(CU) was assigned to 8000 RLU.

QUANTA Flash DGP IgG   
The control population for establishing the reference interval for the DGP IgA assay consisted of 392   
subjects:

<table><tr><td rowspan=1 colspan=1>Apparently healthy blood bank donors</td><td rowspan=1 colspan=1>201</td></tr><tr><td rowspan=1 colspan=1>Inflammatory bowel disease</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>H. pylori infection</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>Autoimmune thyroid disease</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>Controls tTG workshop study from Dr. Liu atChildren&#x27;s Hospital and University of Colorado.</td><td rowspan=1 colspan=1>50</td></tr></table>

All specimens were the same matrix (serum) as specified in the Intended Use. All specimens were unaltered. The cut off was established in accordance to CLSI C28-A3c: Defining, Establishing, and Veriying Reference Intervals in the Clinical Laboratory Approved Guideline Third Edition.The Analyse it forExcel software was used to make the calculations. The distribution of the results was non-normal (Saphiro-Wilk $\mathsf { p } { < } 0 . 0 0 0 1 $ , so the non-parametric percentile method was used. The 99th percentile of the RLU values was 19451, and the 98th percentile value was 9800. The cut-off was finally established at 15000 RLU. This value provided the combination of the highest sensitivity and specificity based on the results obtained on 37 CD specimens that were tested together with the control population. The value of 20 chemiluminescent units (CU) was assigned to 15000 RLU.

# Linearity

# QUANTA Flash DGP IgA:

The linearity of theAMR was evaluated by a stud according to CLS EP-A, Evaluation of the Lineariy o Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline. Six serum samples with various DGP IgA concentrations were diluted with a low negative serum to obtain values that cover the whole AMR. All specimens showed dilution linearity individually, and the combined data yielded the following results with linear regression:

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Test Range (CU)</td><td rowspan=1 colspan=1>Slope (95% Cl)</td><td rowspan=1 colspan=1>Y-intercept (95% CI)</td><td rowspan=1 colspan=1>R^{2}$</td></tr><tr><td rowspan=1 colspan=1>All Samples</td><td rowspan=1 colspan=1>5.2 to 2596.8</td><td rowspan=1 colspan=1>1.05 (1.03 to 1.07)</td><td rowspan=1 colspan=1>6.19 (-8.49 to 20.86)</td><td rowspan=1 colspan=1>0.99</td></tr></table>

# QUANTA Flash DGP IgG:

The linearity of the AMR was evaluated by a study according to CLSI EP-A, Evaluation of the Linearity o Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline. Six serum samples with various DGP IgG concentrations were diluted with a low negative serum to obtain values that cover the whole AMR. All six specimens showed dilution linearity individually, and the combined data yielded the following results with linear regression:

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Test Range (CU)</td><td rowspan=1 colspan=1>Slope (95% Cl)</td><td rowspan=1 colspan=1>Y-intercept (95% CI)</td><td rowspan=1 colspan=1>R^{2}$</td></tr><tr><td rowspan=1 colspan=1>All Samples</td><td rowspan=1 colspan=1>3.6 to 2565.4</td><td rowspan=1 colspan=1>1.03 (1.02 to 1.04)</td><td rowspan=1 colspan=1>4.78 (-4.99 to 14.54)</td><td rowspan=1 colspan=1>1.00</td></tr></table>

# Auto-rerun function

TBIO-LASH otwarsute t valabl  h tin s elecetm ill automatically rerun any sample that has a result >2367.3 CU for DGP IgA or >1936.7 for DGP IgG, by further diluting it by a factor  10, and calculating the actual U using this additinaldilutin aco.

To confirm the Auto-rerun function, two high positive specimens with results above the analytical measuring range were selected for each assay. The samples were run with the Auto-rerun function enabled on the BIO-FLASH. Then the specimens were manually diluted the same way as it happens in the Auto-rerun function (10 fold dilution), and tested on the BIO-FLASH. The results were within the analytical measuring range after auto-rerun or manual dilution for all specimens. The differences between the manual and automatic results for DGP IgA were $1 1 \%$ and $1 5 \%$ , and for the DGP IgG $1 9 \%$ and $5 \%$ (within the $\pm 2 0 \%$ acceptance limit).

# High concentration hook effect

Toasess hook effect, the measurement sinal (relative ight unit, RLU) was examined or high positive specimens with results above the analytical measuring range before and after automatic or manual dilution. All sera produced significantly higher RLU values when used "as is" compared to the manually or automatically diluted ones, thereby confirming that high positive specimens above the analytical measuring range do not show hook effect up to 5167.2 CU in the DGP IgA assay and up to 4323.7 CU in the DGP IgG assay.

# Interference

# QUANTA Flash DGP IgA:

The interference study was performed according to CLSI EP07-A2, Interference Testing in Clinical Chemistry; Approved Guideline - Second Edition. Three specimens were tested. Interfering substances were spiked into every specimen at three different concentrations in $10 \%$ of total specimen volume, and the resulting samples were assessed in triplicates with the DGP IgG assay. Recovery of the unit values was calculated compared to control samples spiked with the same volume of diluents. Acceptance criteria for the interference studies were $8 5 \% - 1 1 5 \%$ recovery, or $+ 1$ - 4 CU difference, whichever is greater.

No interference was detected with hemoglobin up to 200 mg/dl (recovery 88.9-114.4%) and triglycerides up to $\scriptstyle 1 0 0 0 m \geq / \alpha L$ and cholesterol up to 224.3 mg/dL (recovery 100.2-110.1%). No interference was detected with bilirubin up to 10 mg/dL (recovery: 96.0-114.6%) in two specimens. One specimen showed 116.1% recovery when spiked with 5 mg/dl bilirubin; however, no interference could be detected when the same specimen was spiked with 10 mg/dl bilirubin (recovery $1 0 9 . 9 \% )$ or when the other specimens were spiked with the same concentration of bilirubin. No interference was detected with RF IgM up to $5 0 0 1 0 / m L$ (recovery 86.8-98.5%). One specimen showed $7 6 . 3 \%$ recovery when spiked with 500 IU/mL RF; however, no interference was detected when the same specimen was spiked with 100 and $3 0 0 1 1 1 / m L$ RF (recovery 94.1 and $9 8 . 5 \% 1$ , or when the other two specimens were spiked with 500 1U/mL.

QUANTA Flash DGP IgG:

The interference study was performed according to CLSI EP07-A2, Interference Testing in Clinical Chemistry; Approved Guideline - Second Edition. Five specimens were tested. One specimen (6.2 CU) was excluded from the final calculations, as some of the measurement results were below the analytical measuring range (5.2 CU). Interfering substances were spiked into every specimen at three different concentrations in $10 \%$ of total specimen volume, and the resulting samples were assessed in triplicates with the DGP IgG assay. Recovery of the unit values was calculated compared to control samples spiked with the same volume of diluents. Acceptance criteria for the interference studies were $8 5 \% - 1 1 5 \%$ recovery, or $+ 1$ 4 CU difference, whichever is greater.

No interference was detected with bilirubin up to 10 mg/dL (recovery: 104-108%), hemoglobin up to 200 mg/dL (recovery 100-110%), triglycerides up to 1000 mg/dl (recovery 104-107%), and cholesterol up to 224.3 mg/dL (recovery 104-107%). No interference was detected with RF IgM up to 500 IU/mL in three specimens (recovery 99-112%). One specimen showed $13 7 \%$ recovery when spiked with 100 IU/mL RF only; however, no interference was detected when the same specimen was spiked with 300 and 500 IU/mL RF (recovery $108 \%$ and $1 1 2 \%$ ), or when the other three specimens were spiked with the same concentration of RF.

# Cross-reactivity

# QUANTA Flash DGP IgA:

To test potential cross-reactivity with autoantibodies and infection-induced antibodies, 201 patient samples were tested from patients with infectious diseases, autoimmune diseases and connective tissue diseases, including those characterized with gastrointestinal symptoms. None of those specimens were positive in the DGP IgA test.

# QUANTA Flash DGP IgG:

To test potential cross-reactivity with autoantibodies and infection-induced antbodies, 185 patient samples were tested from patients with infectious diseases, autoimmune diseases and connective tissue diseases, including those characterized with gastrointestinal symptoms. Twout of the1 viral hepatitis, two out of the 7 H. pylori infection, and one out of the 37 rheumatoid arthritis specimens were positive with the DGP IgG assay. Altogether, only five out of the 185 specimens (3%) were positive, indicating the lack of cross-reactivity.

# Comparison with predicate device

# QUANTA Flash DGP IgA:

Samples for ethod comparison analyis included those amples rom the cinical validation studies (CD, onCD and dermatitis herpetiformis patients) that were within the AMR of the QUANTA Flash DGP IgA assay. These samples were tested on both the QUANTA Flash DGP IgA and on the predicate ELISA.

<table><tr><td rowspan=2 colspan=2>Method Comparison (N=96)</td><td rowspan=1 colspan=3>DGP IgA ELISA</td><td rowspan=2 colspan=1>Percent Agreement(95% Confidence)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>QUANTAFlash T™ DGPIgA CIA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>3*</td><td rowspan=1 colspan=1>68</td><td rowspan=1 colspan=1>Pos. Agreement = 91.5% (82.5-96.8%)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>6**</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>Neg. Agreement = 90.3% (74.2-98.0%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>Total Agreement = 91.2% (83.9-95.9%)</td></tr><tr><td rowspan=1 colspan=6>* Two patients are suspected CD with no diagnosis, while the third is a DH patient.   has ulcerative colitis.</td></tr></table>

# DGP IgA method comparison on DH samples:

<table><tr><td rowspan=2 colspan=2>Method Comparison (N=21)</td><td rowspan=1 colspan=3>DGP IgA ELISA</td><td rowspan=2 colspan=1>Percent Agreement(95% Confidence)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>QUANTAFlash ™ DGPIgA CIA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>Pos. Agreement = 85.7% (57.2%-98.2%)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>Neg. Agreement = 85.7% (42.1-99.6%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>Total Agreement = 85.7% (63.7%-97.0%)</td></tr></table>

# QUANTA Flash DGP IgG:

Samples formethod comparison analysis included those samples rom the clinical validation studies (CD, onCD and DH patients) that were within the AMR of the QUANTA Flash DGP IgG assay. These samples were tested on both the QUANTA Flash DGP IgG and on the predicate ELISA.

<table><tr><td rowspan=2 colspan=2>Method Comparison (N=235)</td><td rowspan=1 colspan=3>DGP IgG ELISA</td><td rowspan=2 colspan=1>Percent Agreement(95% Confidence)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>QUANTAFlash ™ DGPIgG CIA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>26*</td><td rowspan=1 colspan=1>104</td><td rowspan=1 colspan=1>Pos. Agreement = 95.1% (88.0-98.7%)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>4**</td><td rowspan=1 colspan=1>133</td><td rowspan=1 colspan=1>137</td><td rowspan=1 colspan=1>Neg. Agreement = 83.6% (77.0-89.0%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>159</td><td rowspan=1 colspan=1>241</td><td rowspan=1 colspan=1>Total Agreement = 87.6% (82.7-91.4%)</td></tr></table>

gastrointestinal symptoms at time of sample collection, with two being IgA anti-h-tTG positive.

\*Three samples are from CD patients, and one is from a DH patient.

# DGP IgG method comparison on DH samples:

<table><tr><td rowspan=2 colspan=2>Method Comparison (N=21)</td><td rowspan=1 colspan=3>DGP IgG ELISA</td><td rowspan=2 colspan=1>Percent Agreement(95% Confidence)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>QUANTAFlash ™ DGPIgG CIA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>Pos. Agreement = 88.9% (65.3%-98.6%)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Neg. Agreement = 100.0% (47.8%-100.0%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>Total Agreement = 91.3% (72.0%-98.9%)</td></tr></table>

# DGP IgG method comparison on IgA deficient samples:

<table><tr><td rowspan=2 colspan=2>Method Comparison (N=21)</td><td rowspan=1 colspan=3>DGP IgG ELISA</td><td rowspan=2 colspan=1>Percent Agreement(95% Confidence)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>QUANTAFlash T™ DGPIgG CIA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>Pos. Agreement = 71.4% (29.0%-96.3%)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>Neg. Agreement = 66.7% (22.3%-95.7%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>Total Agreement = 69.2% (38.6%-90.9%)</td></tr></table>

# Clinical sensitivity, specificity

# QUANTA Flash DGP IgA:

The clinical validation study included 54 CD samples from INOvA's serum library, 39 samples from patients with CD but on gluten free diet or with unconfirmed CD, 103 non-celiac disease controls, and 21 samples from patients with DH. A separate external study included 93 CD samples, 151 samples from individuals seeking medical attention in whom CD was excluded based on physical exam and diagnostic tests, and 98 disease controls. The 151 samples consisted of 58 samples from adults and 93 samples from pediatric population. Clinical symptoms of these subjects were consistent with suspected CD:

gastrointestinal symptoms, fatigue, and/or anemia. These samples were tested with the QuANTA Flash DGP IgA CIA. Results obtained on healthy blood donors were not included in the clinical sensitivity and y an p  i y.

Tlt wnalyz  lculativiy n y $( n = 1 4 7$ and DH $( n = 2 1 )$ separately using the same control population $( n = 3 5 2 )$ .

When divided according to age, the QUANTA Flash™ DGP IgA test was performed on 43 serum samples from infants, 96 serum samples from children, 36 serum samples from adolescents, and 324 serum samples from adults. Sera from al pediatric groups howe smilar sensitivity and specficity values as the adult population, therey demnstrating theutility  the ame cut- (0 ). The result  thi testing are shown in the Tables below:

Clinical sensitivity and specificity of the QUANTA Flash™ DGP IgA assay in CD:   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Diagnosis</td><td rowspan=2 colspan=1>Analysis(95% confidence)</td></tr><tr><td rowspan=1 colspan=1>CD</td><td rowspan=1 colspan=1>Not CD</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>QUANTA Flash™. DGP IgA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>Sensitivity = 71.4% (63.4-78.6%)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>42*</td><td rowspan=1 colspan=1>352</td><td rowspan=1 colspan=1>394</td><td rowspan=1 colspan=1>Specificity = 100.0% (99.0-100%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>147</td><td rowspan=1 colspan=1>352</td><td rowspan=1 colspan=1>499</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=6>        Marsh II, and 11 had no biopsy result.</td></tr></table>

# The distribution and DGP IgA positivity rate in the disease control population:

<table><tr><td rowspan=1 colspan=1>Patient Group</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1># of positives</td></tr><tr><td rowspan=1 colspan=1>Autoimmune liver disease</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Viral hepatitis</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Inflammatory bowel disease (Chron +UC)</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>H pylori infection</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Food allergy</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Systemic rheumatic disease</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Autoimmune thyroid disease</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Patients with gastrointestinal symptoms</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Type 1 diabetes mellitus</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid arthritis</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Other infectious disease (HIV, Syphilis)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>201</td><td rowspan=1 colspan=1>0</td></tr></table>

Summary of sensitivity and specificity values in CD according to age groups:   

<table><tr><td rowspan=1 colspan=1>Age group</td><td rowspan=1 colspan=2>DGP IgA</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Sensitivity, %</td><td rowspan=1 colspan=1>Specificity, %</td></tr><tr><td rowspan=1 colspan=1>1 month - 2 years</td><td rowspan=1 colspan=1>50.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>2 years - 12 years</td><td rowspan=1 colspan=1>66.7</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>12-21 years</td><td rowspan=1 colspan=1>58.3</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>&gt;21 years</td><td rowspan=1 colspan=1>77.4</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>&lt; 21 years (total)</td><td rowspan=1 colspan=1>63.5</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>71.4</td><td rowspan=1 colspan=1>100.0</td></tr></table>

Diagnostic sensitivity and specificity were calculated on the DH group separately, and the results e shown in the Table below.

Clinical sensitivity and specificity of the QUANTA Flash™ DGP IgA assay in DH:   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Diagnosis</td><td rowspan=2 colspan=1>Analysis(95% confidence)</td></tr><tr><td rowspan=1 colspan=1>DH</td><td rowspan=1 colspan=1>Not DH</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>QUANTA Flash™DGP IgA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>Sensitivity = 61.9% (38.4-81.9%)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>8*</td><td rowspan=1 colspan=1>352</td><td rowspan=1 colspan=1>360</td><td rowspan=1 colspan=1>Specificity = 100.0% (99.0-100%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>352</td><td rowspan=1 colspan=1>373</td><td rowspan=1 colspan=1>cnmaGellowb</td></tr><tr><td rowspan=1 colspan=6>*Six samples were also negative on the DGP IgA EIA.</td></tr></table>

ROC analysis was performed on the validation sample pool for CD and DH (excluding CD patients on gluten-free diet). The results are below:

# Celiac Disease:

<table><tr><td>Test</td><td>Area</td><td>95% Cl</td><td>SE</td><td>z</td><td>p</td></tr><tr><td>DGP IgA</td><td>0.94</td><td>0.90 to 0.97</td><td>0.018</td><td>24.93</td><td>&lt;0.0001</td></tr></table>

# Dermatitis Herpetiformis:

<table><tr><td>Test</td><td>Area</td><td>95% Cl</td><td>SE</td><td>z</td><td>p</td></tr><tr><td>DGP IgA</td><td>0.79</td><td>0.63 to 0.96</td><td>0.082</td><td>3.57</td><td>0.0002</td></tr></table>

# QUANTA Flash DGP IgG:

The clinical validation study included 62 CD samples from INovA's serum library (including 7 with selective IgA deficiency), 87 non-celiac disease controls, 39 samples from patients with CD but on gluten free diet or with unconfirmed CD, and 23 samples from patients with DH. A separate external study included 102 CD samples (including 9 with selective IgA deficiency), 151 samples from individuals seeking medical attention in whom CD was excluded after physical exam and diagnostic tests, and 98 disease controls. The 151 samples consisted of 58 samples from adults and 93 samples from pediatric population. Clinical symptoms of these subjects were consistent with suspected CD: gastrointestinal symptoms, fatigue, and/or anemia. These samples were tested with the QUANTA Flash DGP IgG CIA. Results obtained on healthy blood donors were not included in the clinical sensitivity and specificity calculations. Four of the control samples were weak positive $( < 3 0 . 0 0 )$ in the DGP IgG assay.

Te eult wenalyz  clcla nsiiviy n e $( n = 1 4 8 )$ CD with IgA deficiency $( n = 1 6 )$ and DH $( n = 2 3 )$ separately using the same control population $( n = 3 3 6 )$ .

When divided according to age, the QuANTA Flash™ IgG test was performed on 43 serum samples from infants, 96 serum samples from children, 35 serum samples from adolescents and 310 serum samples from adults. Sera from all pediatric groups showed similar sensitivity and specificity values as of the adult population, thereby demonstrating the utility of the same cut-off (20 CU).

Clinical sensitivity and specificity of the QUANTA Flash DGP IgG assay in CD:   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Diagnosis</td><td rowspan=2 colspan=1>Analysis(95% confidence)</td></tr><tr><td rowspan=1 colspan=1>CD</td><td rowspan=1 colspan=1>Not CD</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>QUANTA Flash™DGP IgG</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>132</td><td rowspan=1 colspan=1>g*</td><td rowspan=1 colspan=1>141</td><td rowspan=1 colspan=1>Sensitivity = 89.2% (83.0-93.7%)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>16**</td><td rowspan=1 colspan=1>327</td><td rowspan=1 colspan=1>343</td><td rowspan=1 colspan=1>Specificity = 97.3% (95.0-98.8%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>148</td><td rowspan=1 colspan=1>336</td><td rowspan=1 colspan=1>484</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=6>Two samples have H. pylori gastritis, two have viral hepatitis, and one has rheumatoid arthritis.             Marsh 11, and 7 had no biopsy result.</td></tr></table>

Altogether 16 samples were from IgA deficient CD patients. Nine out of 16 (56.3%) were positive with the DGP IgG assay, indicating that the assay is a useful tool for CD screening in IgA deficient subjects.

Clinical sensitivity and specificity of the QUANTA Flash DGP IgG assay in IgA deficient CD:   

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Diagnosis</td><td rowspan=2 colspan=1>Analysis(95% confidence)</td></tr><tr><td rowspan=1 colspan=1>CD (IAdeficient)</td><td rowspan=1 colspan=1>Not CD</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>QUANTA Flash™DGP IgG</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>Sensitivity = 56.3% (29.9-80.2%)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>327</td><td rowspan=1 colspan=1>334</td><td rowspan=1 colspan=1>Specificity = 97.3% (95.0-98.8%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>336</td><td rowspan=1 colspan=1>352</td><td rowspan=1 colspan=1></td></tr></table>

# The distribution and positivity rate in the disease control population:

Summary of sensitivity and specificity values in CD according to age groups:   

<table><tr><td rowspan=1 colspan=1>Patient Group</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1># of positives</td></tr><tr><td rowspan=1 colspan=1>Autoimmune liver disease</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Viral hepatitis</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Inflammatory bowel disease (Chron +UC)</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>H pylori infection</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Food allergy</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Systemic rheumatic disease</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Autoimmune thyroid disease</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Patients with gastrointestinal symptoms</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Type 1 diabetes mellitus</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid arthritis</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Other infectious disease (HIV, Syphilis)</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>185</td><td rowspan=1 colspan=1>5</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Age group</td><td rowspan=1 colspan=2>DGP IgG</td></tr><tr><td rowspan=1 colspan=1>cYanmaGentaYellowb</td><td rowspan=1 colspan=1>Sensitivity, %</td><td rowspan=1 colspan=1>Specificity, %</td></tr><tr><td rowspan=1 colspan=1>1 month -2 years</td><td rowspan=1 colspan=1>66.7</td><td rowspan=1 colspan=1>94.6</td></tr><tr><td rowspan=1 colspan=1>2 years - 12 years</td><td rowspan=1 colspan=1>95.6</td><td rowspan=1 colspan=1>96.1</td></tr><tr><td rowspan=1 colspan=1>12-22 years</td><td rowspan=1 colspan=1>75.0</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>&gt;21 years</td><td rowspan=1 colspan=1>89.4</td><td rowspan=1 colspan=1>97.8</td></tr><tr><td rowspan=1 colspan=1>&lt; 21 years (total)</td><td rowspan=1 colspan=1>88.9</td><td rowspan=1 colspan=1>96.4</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>89.2</td><td rowspan=1 colspan=1>97.3</td></tr></table>

Diagnostic sensitivity and specificity were calculated on the DH group separately, and the results re shown in the Table below.

Clinical sensitivity and specificity of the QUANTA Flash DGP IgG assay in DH:

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Diagnosis</td><td rowspan=2 colspan=1>Analysis(95% confidence)</td></tr><tr><td rowspan=1 colspan=1>DH</td><td rowspan=1 colspan=1>Not DH</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>QUANTA Flash™DGP IgG</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>g*</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>Sensitivity = 69.6% (47.1-86.8%)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>7**</td><td rowspan=1 colspan=1>327</td><td rowspan=1 colspan=1>334</td><td rowspan=1 colspan=1>Specificity = 97.3% (95.0-98.8%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>336</td><td rowspan=1 colspan=1>359</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=6>*Two samples have H. pylori gastritis, two have viral hepatitis, and one has rheumatoid arthritis.*Fi samples were also negative on the DGP IgG EIA.</td></tr></table>

ROC analysis was performed on the validation sample pool for CD and DH (excluding CD patients on gluten-free diet). The results are below:

# Celiac Disease:

<table><tr><td>Test</td><td>Area</td><td>95% CI</td><td>SE</td><td>Z</td><td>p</td></tr><tr><td>DGP IgG</td><td>0.99</td><td>0.98 to 1.00</td><td>0.004</td><td>127.74</td><td>&lt;0.0001</td></tr></table>

# Dermatitis Herpetiformis:

<table><tr><td>Test</td><td>Area</td><td>95% CI</td><td></td><td>SE</td><td>Z</td><td>p</td></tr><tr><td>DGP IgG</td><td>0.95</td><td>0.91</td><td>to 1.00</td><td>0.021</td><td>21.49</td><td>&lt;0.0001</td></tr></table>

# Stability

# Shelf life

The QUANTA Flash DGP IgA and IgG assay kits, as well as the QUANTA Flash DGP IgA and IgG Calibrators and the QUANTA Flash DGP IgA and IgG Controls have a shelf life of one year.

In-use stability

The QUANTA Flash DGP IgA reagent cartridge in-use (on-board) stability is 40 days.   
The QuANTA Flash DGP IgG reagent cartridge in-use (on-board) stability is 62 days.

Both the QUANTA Flash DGP IgA and IgG Calibrators can be used for up to 4 calibrations over an 8 hou period.

The QUANTA Flash DGP IgA and IgG Controls can be used for up to 15 times, with a maximum time of 10 minutes onboard the instrument per use. The total time the control tubes can be uncapped onboard the instrument is 2 ½ hours.

# OCT 23 2012

INOVA Diagnostics, Inc.   
c/o Gabriella Lakos, M.D., Ph.D. Director of Research, Rheumatology 9900 Old Grove Road   
San Diego, CA 92131

Re: k113863 Trade/Device Name: QUANTA FlashTM DGP IgA QUANTA FlashTM DGP IgA Calibrators QUANTA FlashTM DGP IgA Controls QUANTA Flash™M DGP IgG QUANTA FlashTM DGP IgG Calibrators QUANTA FlashTM DGP IgG Controls

Regulation Number: 21 CFR §866.5750   
Regulation Name: Radioallergosorbent (RAST) Immunological Test System   
Regulatory Class: Class II   
Product Code: MST, JIX, JJX   
Dated: September 20, 2012   
Received: September 20, 2012

Dear Dr. Lakos:

This letter corrects our substantially equivalent letter of September 20, 2012. We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Page 2 - Gabriella Lakos, M.D., Ph.D.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to   
http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Maria M. Chan, Ph.D.   
Director   
Division of Immunology and Hematology Devices Office of In Vitro Diagnostics and   
Radiological Health   
Center for Devices and Radiological Health

Enclosure

# Indications for Use Form

510(k) Number (if known): /1365 Device Name: . QUANTA FlashTM DGP IgA Controls

Indications for Use:

The QUANTA Flash DGP IgA Controls are intended for quality control purposes of the QUANTA Flash DGP IgA chemiluminescent immunoassay (CIA) kit run on the BIO FLASH ® Instrument that is used for the measurement of IgA anti-deamidated gliadin peptide (DGP) antibodies in human serum.

# Indications for Use Form

510(k) Number (if known): K1138 6 3 Device Name: QUANTA FlashTM DGP IgG Controls

Indications for Use:

The QUANTA Flash DGP IgG Controls are intended for quality control purposes of the QUANTA Flash DGP IgG chemiluminescent immunoassay (CIA) kit run on the BIO FLASH ® Instrument that is used for the measurement of IgG anti-deamidated gliadin peptide (DGP) antibodies in human serum.

Indications for Use

# 510(k) Number (if known): k113863

Device Name: QUANTA Flash™M DGP IgA

. Indications For Use:

The QUANTA FlashTM DGP IgA is a chemiluminescent immunoassay for the semiquantitative determination of IgA antibodies to synthetic, deamidated gliadin peptides in human serum. The presence of IgA deamidated gliadin peptide antibodies can be used in conjunction with clinical findings and other laboratory tests to aid in the diagnosis of celiac disease and dermatitis herpetiformis.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/6f9262a0746f78102c5b96dad200a777c012c21d76dc257744c94880fb484167.jpg)

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety 510K K113863

# Indications for Use

# 510(k) Number (if known): k113863

Device Name: QUANTA Flash™M DGP IgG

Indications For Use:

The QUANTA FlashTM DGP IgG is a chemiluminescent immunoassay for the semiquantitative detection of IgG antibodies to synthetic, deamidated gliadin peptides in human serum. The presence of IgG deamidated gliadin peptide antibodies can be used in conjunction with clinical findings and other laboratory tests to aid in the diagnosis of celiac disease in both IgA sufficient and IgA deficient subjects, as well as dermatitis herpetiformis.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED).

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

7   
Division Sign-Off   
Office of In Vitro Dlagnostic   
Device Evaluation and Safety   
510K K113863

# Indications for Use

510(k) Number (if known): k113863

Device Name: QUANTA Flash™M DGP IgA Calibrators

Indications For Use:

he QUANTA FlashTM DGP IgA Calibrators are intended for use with the QUANTA Flash™M DGP IgA chemiluminescent immunoassay to establish points of reference for the working curve that is used to determine Chemiluminescent Unit (CU) values in the measurement of IgA anti-DGP antibodies in serum.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/c437623ce924591986febe5c6c9e0438148bad06bd6f60d3bc363c48188fb97b.jpg)

Office of In Vitro Diagnostic Device Evaluation and Safety 510K_ K113863.

Indications for Use

# 510(k) Number (if known): k113863

Device Name: QUANTA Flash™M DGP IgG Calibrators

Indications For Use:

The QUANTA FlashTM DGP IgG Calibrators are intended for use with the QUANTA FlashTM DGP IgG chemiluminescent immunoassay to establish points of reference for the working curve that is used to determine Chemiluminescent Unit (CU) values in the measurement of IgG anti-DGP antibodies in serum.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/fb383c031aac7c23efbb9ee60e51de41715e1b5eb72ea5785d42a6d96ffecfc0.jpg)

# Division Sign-Off

Office of In Vitro Diagnostlc Device Evaluation and Safety 510KK113863